Free Trial

Revolution Medicines (RVMD) Stock Forecast & Price Target

$44.06
+0.29 (+0.66%)
(As of 09/18/2024 ET)

Revolution Medicines - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 12 Wall Street analysts who have issued ratings for Revolution Medicines in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 11 have given a buy rating, and 1 has given a strong buy rating for RVMD.

Consensus Price Target

$52.92
20.10% Upside
High Forecast$63.00
Average Forecast$52.92
Low Forecast$40.00

According to the 12 analysts' twelve-month price targets for Revolution Medicines, the average price target is $52.92. The highest price target for RVMD is $63.00, while the lowest price target for RVMD is $40.00. The average price target represents a forecasted upside of 20.10% from the current price of $44.06.

TypeCurrent Forecast
9/19/23 to 9/18/24
1 Month Ago
8/20/23 to 8/19/24
3 Months Ago
6/21/23 to 6/20/24
1 Year Ago
9/19/22 to 9/19/23
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
11 Buy rating(s)
9 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$52.92$52.92$43.20$33.67
Forecasted Upside20.10% Upside35.86% Upside33.66% Upside16.89% Upside

RVMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RVMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Revolution Medicines Stock vs. The Competition

TypeRevolution MedicinesMedical CompaniesS&P 500
Consensus Rating Score
3.08
2.77
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside20.10% Upside1,009.48% Upside7.94% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/12/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$56.00 ➝ $56.00+30.54%
8/8/2024JPMorgan Chase & Co.
3 of 5 stars
 Lower TargetOverweight ➝ Overweight$55.00 ➝ $54.00+27.30%
8/8/2024Wedbush
3 of 5 stars
 Reiterated RatingOutperform ➝ Outperform$59.00 ➝ $59.00+40.28%
8/8/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$62.00 ➝ $61.00+44.31%
7/18/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Lawson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$52.00 ➝ $54.00+17.37%
7/16/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$45.00 ➝ $55.00+19.57%
Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad)

Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.

Click here to see it because it’s a SHOCKER…
7/16/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$48.00 ➝ $55.00+19.57%
7/8/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$63.00+67.87%
4/10/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeOutperform ➝ Strong-Buy$36.00 ➝ $48.00+45.50%
3/11/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$43.00+33.33%
12/20/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$40.00+46.84%
9/21/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$37.00 ➝ $47.00+58.09%
3/1/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$20.00 ➝ $23.00-13.60%
2/28/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$38.00+38.18%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:50 PM ET.

RVMD Forecast - Frequently Asked Questions

What is Revolution Medicines' forecast for 2024?

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Revolution Medicines is $52.92, with a high forecast of $63.00 and a low forecast of $40.00.

Should I buy or sell Revolution Medicines stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last year. There are currently 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVMD shares.

Does Revolution Medicines's stock price have much upside?

According to analysts, Revolution Medicines's stock has a predicted upside of 35.86% based on their 12-month stock forecasts.

What analysts cover Revolution Medicines?

Revolution Medicines has been rated by research analysts at Bank of America, Barclays, HC Wainwright, Jefferies Financial Group, JPMorgan Chase & Co., Needham & Company LLC, Oppenheimer, and Wedbush in the past 90 days.

Do Wall Street analysts like Revolution Medicines more than its competitors?

Analysts like Revolution Medicines more than other "medical" companies. The consensus rating for Revolution Medicines is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RVMD compares to other companies.



This page (NASDAQ:RVMD) was last updated on 9/18/2024 by MarketBeat.com Staff
From Our Partners